En el estudio Scale Sleep Apnea, personas con obesidad (IMC 39,1kg/m2) sin DM2 y con AOS moderada (IAH 15-29,9 eventos por hora) o grave (IAH 30 eventos por hora) sin CPAP fueron aleatorizadas a recibir durante 32 semanas liraglutida 3mg (n=180) o placebo (n=179), junto con dieta y ejercicio15
This rebound can also reignite obesity-related health issues like type 2 diabetes, heart disease, and sleep apnea
no trials have been conducted in BN, and high rates of diagnostic crossover to anorexia nervosa (AN) raise additional safety and ethical concerns [22, 23]
Our findings indicate that patients treated with semaglutide, particularly at higher doses such as Wegovy (2.4 mg), exhibited a higher incidence of psychiatric outcomes compared to non-GLP-1 RA users
Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes a Danish nationwide observational study
Oral GLP-1 drugs may make taking GLP-1 drugs easier as they do not require people to self-inject medication